Brown JWL, et al. - Investigators assessed 1,555 patients with relapsing-remitting multiple sclerosis (MS) to examine the relationship between the application, the type of, and the timing of disease-modifying treatments (DMTs) with the risk of conversion to secondary progressive multiple sclerosis (MS). They observed initial treatment with fingolimod, alemtuzumab, or natalizumab linked to a lower risk of conversion to secondary progressive MS vs initial treatment with glatiramer acetate or interferon beta among these patients. They noticed that considering the outcome obtained along with the risk of such treatments might prove beneficial during making decisions about DMT selection.